What is S-Matrix?
S-Matrix Corporation is a key player in the pharmaceutical development sector, offering the Fusion QbD Software Platform. This advanced solution leverages expert-system guided statistical Design of Experiments (DOE) and multivariate data analysis within a Quality by Design (QbD) framework. Pharmaceutical companies worldwide utilize S-Matrix's offerings for critical processes such as analytical method development, validation, and transfer, alongside formulation and process development. Regulatory agencies also employ the software to modernize methods and validate the robustness of pharmaceutical submissions, highlighting S-Matrix's integral role in ensuring compliance and innovation within the industry.
How much funding has S-Matrix raised?
S-Matrix has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in S-Matrix
PPP
Public-Private Partnership
What's next for S-Matrix?
With its recent strategic investment, S-Matrix is poised for significant expansion and further development of its QbD software solutions. The substantial capital indicates a focus on scaling operations, enhancing product capabilities, and potentially broadening its market reach within the global pharmaceutical and regulatory landscapes. This funding will likely accelerate innovation in areas such as AI-driven statistical analysis and cloud-based deployment, solidifying S-Matrix's leadership in facilitating efficient and compliant drug development.
See full S-Matrix company page
